Medicure

WINNIPEG, MB / ACCESS Newswire / March 11, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that further to its news release on February 18, 2025, through its wholly-owned U.S. subsidiary Medicure Pharma Inc., it has closed on the acquisition of 100% of Gateway Medical Pharmacy Inc. ("Gateway") from an arms-length third-party (the "Transaction"). As previously disclosed, the acquisition of Gateway aligns with Medicure's strategic plan for the expansion of the Company's direct-to-consumer pharmacy business, and positions Medicure to accelerate its growth of ZYPITAMAG® and its other products and services.» Mehr auf accessnewswire.com

WINNIPEG, MB / ACCESS Newswire / February 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it has signed a definitive agreement on February 14, 2025 to acquire 100% of Gateway Medical Pharmacy Inc. ("Gateway") from an arms-length third-party (the "Proposed Transaction"). Gateway generated unaudited revenue of approximately $3.1 million and net income of $271,000 for the 12-month period ended December 31, 2024.» Mehr auf accessnewswire.com

WINNIPEG, MB / ACCESSWIRE / November 25, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2024. Quarter Ended September 30, 2024 Highlights: Recorded total net revenue of $5.2 million during the quarter ended September 30, 2024 compared to $5.0 million for the quarter ended September 30, 2023 and; Recorded total net revenue from the sale of AGGRASTAT® of $1.9 million during the quarter ended September 30, 2024 compared to $2.4 million for the quarter ended September 30, 2023 and; Recorded total net revenue from the Marley Drug business of $2.7 million ($815,000 from sales of ZYPITAMAG®, and $1.9 million from other pharmacy revenue) during the quarter ended September 30, 2024 compared to $2.2 million ($670,000 from sales of ZYPITAMAGand $1.5 million from other pharmacy revenue) for the quarter ended September 30, 2023 and; Recorded total net revenue from the sale of ZYPITAMAG of $1.4 million ($553,000 through insured business, and $815,000 through Marley Drug) during the quarter ended September 30, 2024 compared to $1.1 million ($398,000 through insured business and $670,000 through Marley Drug) for the quarter ended September 30, 2023 and; Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended September 30, 2024 was negative $467,000 compared to adjusted EBITDA of $429,000 for the quarter ended September 30, 2023 and; Net Income for the quarter ended September 30, 2024 was $680,000 or $0.07 per share compared to net income of $84,000 or $0.01 per share for the quarter ended September 30, 2023.» Mehr auf accesswire.com